ArticleVeterinary sciences2025
Breaking the PRRSV-2 Life Cycle in Porcine Alveolar Macrophages: Tylvalosin's Multi-Stage Inhibition.
Article in Veterinary sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome (PRRS) is one of the most serious diseases threatening the swine industry worldwide. However, no satisfactory control strategy has existed until now. In this study, the effectiveness of tylvalosin against PRRSV and the underlying mechanism was investigated. The results showed that in porcine alveolar macrophages (PAMs), tylvalosin can inhibit the replication of the NADC30-like and NADC34-like strains in a dose-dependent manner. It is worth noting that pre-incubation with tylvalosin had no significant inhibitory effect on the NADC30-like strain but did inhibit the NADC34-like strain. Co-incubation of both viruses and tylvalosin or post-incubation with tylvalosin after viral infection inhibited PRRSV. We further analyzed the effect of tylvalosin on different stages of PRRSV replication and found that the stages in the PRRSV life cycle could be blocked by tylvalosin. Tylvalosin has an antiviral effect on all four stages of the NADC34-like strain's infectious cycle but has no effect against the adsorption phase of the NADC30-like strain. These results demonstrated that tylvalosin suppressed PRRSV infection in PAMs and inhibited PRRSV infection at multiple steps of the viral life cycle. This study will contribute to the clinical prevention and control of PRRS and provide a basis for further exploration of the anti-PRRSV effects of tylvalosin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.